Showing results (11-20 of 171) with videos related to
Sort By:
Pageof 18
Blood|June 1, 1985
Platelet-associated immunoglobulin, platelet size, and the effect of splenectomy in the Wiskott-Aldrich syndromeL Corash, B Shafer, R M BlaeseCancer Research|October 28, 1999
Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancerO Wildner, R M Blaese, F CandottiCurrent Protocols in Immunology|April 25, 2008
Measurement of polyclonal immunoglobulin synthesis using the reverse plaque techniqueG Tosato, S E Pike, M BlaeseJournal of Immunology (Baltimore, Md. : 1950)|August 1, 1985
Relationship between immunoglobulin production and immortalization by Epstein Barr virusG Tosato, R M Blaese, R YarchoanGene Therapy|February 24, 1998
Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1T Felzmann, W J Ramsey, R M BlaeseProceedings of the National Academy of Sciences of the United States of America|January 1, 1992
Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection systemC A Mullen, M Kilstrup, R M BlaeseJournal of Immunology (Baltimore, Md. : 1950)|December 1, 1984
Newborn and Wiskott-Aldrich patient B cells can be activated by TNP-Brucella abortus: evidence that TNP-Brucella abortus behaves as a T-independent type 1 antigen in humansB Golding, A V Muchmore, R M BlaeseBirth Defects Original Article Series|January 1, 1975
Immunodeficiency in the Wiskott-Aldrich syndromeR M Blaese, W Strober, T A WaldmannHuman Gene Therapy|November 24, 1999
Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecanO Wildner, R M Blaese, J C MorrisJournal of Immunology (Baltimore, Md. : 1950)|February 1, 1982
T cell-mediated immunoregulation of Epstein Barr virus- (EBV) induced B lymphocyte activation in EBV-seropositive and EBV-seronegative individualsG Tosato, I T Magrath, R M BlaesePageof 18